Market Insights Health Pharmaceuticals Vaccines

Other Vaccines - Western Asia

Western Asia

In Western Asia, the revenue in the market Other Vaccines market is forecasted to reach US$1.03bn in 2024.
It is expected to exhibit an annual growth rate (CAGR 2024-2029) of 10.28%, leading to a market volume of US$1.68bn by 2029.
Comparing globally, United States is projected to generate the highest revenue of US$24,730.00m in 2024.
The demand for other vaccines in Western Asia has been steadily increasing due to the region's growing awareness of the importance of preventive healthcare.

Key regions: Australia, Brazil, United Kingdom, Europe, Canada

Market

Region

Region comparison

Currency

Analyst Opinion

The Other Vaccines market in Western Asia has been experiencing significant growth in recent years.

Customer preferences: As the population in Western Asia continues to grow, so does the demand for vaccines. In addition, there has been a growing awareness of the importance of vaccination in preventing the spread of disease. This has led to an increase in demand for Other Vaccines in the region.

Trends in the market: One of the key trends in the Other Vaccines market in Western Asia is the increasing adoption of new technologies. This has led to the development of more effective and efficient vaccines, which are better able to meet the needs of patients in the region. Another trend is the growing focus on preventative healthcare, which has led to an increased demand for vaccines that can help prevent the spread of disease.

Local special circumstances: One of the unique factors that is driving growth in the Other Vaccines market in Western Asia is the high incidence of infectious diseases in the region. This has led to a greater emphasis on vaccination as a means of preventing the spread of disease. In addition, there is a growing awareness of the importance of vaccination among healthcare professionals and the general public, which has helped to drive demand for Other Vaccines.

Underlying macroeconomic factors: The growing population and increasing urbanization in Western Asia are key macroeconomic factors that are driving growth in the Other Vaccines market. In addition, there is a growing middle class in the region, which has led to an increase in healthcare spending. This has helped to drive demand for Other Vaccines, as more people are able to afford preventative healthcare measures. Finally, there is a growing focus on healthcare in the region, which has led to increased investment in research and development, and the development of new and innovative vaccines.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.